CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AHR signaling

ABSTRACT: Targeting the estrogen signaling pathway has proved to be of great value in the treatment of human breast cancer. Tamoxifen, a selective estrogen receptor modulator (SERM), is the most widely used antiestrogen. However, only 40-50% of patients with estrogen receptor (ER) positive breast cancer benefit from tamoxifen treatment and 30-50% acquire resistance and the disease progresses. Continuous treatment with conventional therapy may contribute to cancer progression in recurring cancers through the accumulation of drug resistant cancer progenitors. We found that MCF7 tamoxifen-resistant (TAM-R) cells possess a significantly higher proportion of cancer progenitor cells than tamoxifen-sensitive MCF7 cells. Our results indicate that the chemokine receptor CXCR4 plays an important role in the m

ORGANISM(S): Homo sapiens

SUBMITTER: John Walker 

PROVIDER: E-GEOD-31831 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress